Trial Profile
A Phase II, Double Blind, Exploratory, Parallel-group, Placebo-controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Drisapersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Acronyms DEMAND II
- Sponsors GlaxoSmithKline; GSK
- 20 Nov 2015 Results of pooled analysis of patients with comparable key baseline characteristics from this and two other clinical trials (700242352 and 700242354) published in a BioMarin Pharmaceutical media release.
- 23 Apr 2015 According to BioMarin media release, data presented at the American Academy of Neurology (AAN) Annual Meeting.
- 21 Apr 2015 Results of a pooled analysis of trials DMD114117 and DMD114876 were presented at the 67th Annual Meeting of the American Academy of Neurology.